meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
5
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative
1
mNSCLC - L1 - PDL1 positive
14
mNSCLC - L1 - TMB>10Mb
1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population
3
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT)
6
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population
4
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
immune chekpoint inhibitors
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs pemetrexed plus platin
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
nivolumab plus ipilimumab
title
pemetrexed plus platin
title
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 NCT02477826 mNSCLC - L1 - TMB>10Mb 139/160
Pathology:
mNSCLC - L1 - TMB>10Mb;
mNSCLC - L1 - TMB>10Mb
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018
nivolumab plus ipilimumab
1
T1
pemetrexed plus platin
0
T0